Innate Immunity and Vaccine Adjuvants: From Concepts to the Development of a Unique Adjuvant System AS04 Used for the Formulation of a Human Papillomavirus (HPV) Vaccine

By  

Current Cancer Therapy Reviews, Vol. 6, Iss. 2, 2010-05 ,pp. : 126-137

Bentham Science Publishers

Access to resources Recommend Favorite

Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein–based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia

By Hallez Sophie   Simon Philippe   Maudoux Frédéric   Doyen Jean   Noël Jean-Christophe   Beliard Aude   Capelle Xavier   Buxant Frédéric   Fayt Isabelle   Lagrost Anne-Cécile   Hubert Pascale   Gerday Colette   Burny Arsène   Boniver Jacques   Foidart Jean-Michel   Delvenne Philippe   Jacobs Nathalie  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 7, 2004-07 ,pp. : 642-650

Springer Publishing Company

Access to resources Recommend Favorite

Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States)

By Giuliano A.R.  

Cancer Causes and Control, Vol. 13, Iss. 9, 2002-11 ,pp. : 839-846

Springer Publishing Company

Access to resources Recommend Favorite

Prevalence of Human Papillomavirus (HPV) types in cervical cancer 2003–2008 in Stockholm, Sweden, before public HPV vaccination

By Du Juan   Näsman Anders   Carlson Joseph W.   Ramqvist Torbjörn   Dalianis Tina  

Acta Oncologica, Vol. 50, Iss. 8, 2011-11 ,pp. : 1215-1219

Informa Healthcare

Access to resources Recommend Favorite

Acceptance of human papillomavirus (HPV) vaccination among young women in a country with a high prevalence of HPV infection

By                

International Journal of Oncology, Vol. 43, Iss. 4, 2013-01 ,pp. : 1310-1318

Spandidos Publications

Access to resources Recommend Favorite